Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kinaxo Biotechnologies has collaborated with AstraZeneca, under which Kinaxo will use its technology platform to support one of AstraZeneca's oncology programs.
Subscribe to our email newsletter
Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale.
Kinaxo CTO Henrik Daub said that Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action.
"We are delighted to apply our expertise to support AstraZeneca‘s research in such highly promising fields of investigation," Daub said.